Schering, AstraZeneca form alliance to develop breast cancer drug

By E. Janene Geiss

Philadelphia, Sept. 15 - Schering AG and AstraZeneca have formed an alliance to co-develop and jointly commercialize Schering's novel SERD, a novel selective estrogen receptor downregulator for the treatment of breast cancer.

Under the agreement, the companies said they will jointly develop the SERD with AstraZeneca leading the clinical development and Schering leading the non-clinical and process development, as well as manufacturing activities, the pharmaceutical companies said in a news release.

Berlin-based Schering and London-based AstraZeneca said they will co-promote the product in the major territories. All development and commercialization costs and global profits will be shared equally. Financial terms were not disclosed.

SERDs can potentially be used as monotherapy for treatment of all stages of hormone-sensitive breast cancer or in combination with other targeted agents for the prevention and/or treatment of hormone resistant disease, officials said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.